<h2 dir="ltr">What Are AAV DIO/FLEX Vectors?</h2>
 The DIO (Double-floxed Inverted Open reading frame) architecture &mdash; also called FLEX (FLip-EXcision) or Cre-ON &mdash; is the standard approach for restricting AAV transgene expression to defined cell populations in Cre-driver transgenic mouse lines. The transgene ORF is placed in an antisense (inverted) orientation flanked by two pairs of heterotypic loxP recombination sites until Cre recombinase is present.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" role="presentation">DIO CMV Expression Vectors use the CMV promoter for Cre-dependent and highly specific transgene expression.</li>
<li dir="ltr" role="presentation">Selection-Ready DIO Plasmids used for efficient selection of antibiotics in transduced cells, and feature SV40-Puro markers.</li>
<li dir="ltr" role="presentation">Fluorescent Reporter DIO Vectors carry copGFP or GFP for visually verifying recombination.</li>
<li dir="ltr" role="presentation">Customizable DIO Blank Backbones for insertion of specific genes of interest into a conditional framework.</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV DIO/FLEX Vector</h2>
 Packaging Capacity Constraint AAV DIO vectors are limited to expression cassettes of approximately 4.2 kb due to the ~4.7 kb AAV genome capacity, including the loxP recombination architecture itself &mdash; a key consideration for larger transgenes. Cre-Driver Line Compatibility The vector must be paired with a Cre-driver transgenic mouse line expressing Cre in the cell population of interest, or with co-delivery of a Cre-expressing vector for cell-culture validation. Serotype for Target Region As with standard AAV over-expression, serotype selection determines tissue tropism &mdash; critical for targeting specific brain regions or cell types in neuroscience applications. Permanence of Activation Once Cre flips the ORF into sense orientation and excises one site from each loxP pair, the transgene is permanently locked in the ON orientation &mdash; heritable expression is maintained without continued Cre activity. Validation Strategy Before in vivo injection, co-transfection of the AAV DIO vector with a Cre expression plasmid in HEK293T cells confirms efficient inversion and expected expression; transfecting the DIO vector alone confirms the absence of leaky expression. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
AAV DIO (Double-Floxed Inverted Orientation) vectors are widely used for cell-type-specific conditional gene expression in Cre-driver animal models, supporting applications such as circuit mapping, optogenetics, chemogenetics, and in vivo functional studies. Because transgene expression depends on Cre-mediated recombination, researchers should verify Cre-driver specificity and recombination efficiency in their chosen model before large-scale experiments. Low-level Cre-independent ("leaky") expression can occasionally occur in DIO systems and should be evaluated using appropriate control vectors. The practical packaging capacity of AAV is approximately 4.7 kb, which may limit the size of the transgene cassette that can be accommodated. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team </a>at MBP today and get a quote for premium AAV DIO vector requirements.

Cre-Inducible Gene Expression (DIO) Vectors

Vector Brochure

AAV–General Guideline to Serotype Selection

AAV-Infection Guideline

Lentivirus-Infection Guideline

AAV-CMV-DIO-Blank-SV40-Puro Vector

Unit Quantity

Shipping Condition

AAV-CMV-DIO-copGFP Vector

AAV-CMV-DIO-copGFP-SV40-Puro Vector

<h2 dir="ltr">What Are AAV Control &amp; Reporter Constructs?</h2>
 Establishing reliable experimental controls is critical in AAV research because transduction efficiency varies substantially by serotype, cell type, multiplicity of infection (MOI), and batch-to-batch variation in viral preparation quality. Matched AAV control and reporter constructs provide the reference point for interpreting experimental results.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Promoter-Specific Blank Vectors used for baseline control, utilize neuron-specific hSyn promoters and high-purity plasmids&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Matched Blank Viruses for precise tissue-targeting validation. Available pre-packaged in serotypes 1 through 11
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Bioluminescent Reporter Systems for sensitive measurement of viral delivery.&nbsp; And gene expression featuring luciferase and SV40-luc markers
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Fluorescent Control Constructs carry circ-GFP, GFP, and CBh-gcGFP, for real-time transduction tracking.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Circular RNA Control Plasmids for advanced non-coding RNA research.&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Cloning-Ready Expression Backbones for selected gene insertion and viral packaging workflows using ampicillin-resistant blank vectors
</li>
</ul>
<h2 dir="ltr"> How to Choose AAV Control &amp; Reporter Constructs </h2>
 Serotype and Backbone Matching The control construct should use the same AAV serotype, ITR configuration, and promoter as the experimental construct, ensuring transduction efficiency differences reflect the transgene rather than vector or serotype variation. Fluorescent Reporter Choice GFP and mCherry reporters allow confirmation of transduction by fluorescence microscopy or flow cytometry, with mCherry offering a red-channel option for multiplexed experiments. Luciferase and Dual-Reporter Options Firefly luciferase provides quantitative bioluminescent transduction confirmation; dual reporter systems (e.g., fluorescent + luciferase) allow both visual and quantitative readouts from the same construct. Empty Vector Baseline An empty AAV vector &mdash; same ITRs, serotype, and promoter, no transgene &mdash; establishes the baseline effect of AAV capsid delivery and innate immune activation, independent of the gene of interest. Batch-to-Batch Variation Controls Because AAV preparation quality can vary between batches, including a transduction-efficiency control (e.g., GFP reporter) alongside each new batch of experimental AAV helps confirm comparable functional titer. 
<h2 dir="ltr"> Specifications Context</h2>
 AAV transduction can activate innate immune sensing pathways and, at high vector doses, induce cellular stress responses independently of the transgene. A matched empty vector or reporter control sharing the same serotype and promoter as the experimental construct helps distinguish vector-related effects from genuine transgene-specific phenotypes. Because AAV infectivity can vary between preparations, reporter-based transduction assessments are commonly used to verify functional performance before experimental studies. For in vivo applications, pilot reporter studies can help confirm tissue targeting and delivery efficiency before larger cohorts are committed. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team </a>at MBP today to get high-quality control/reporter vectors for your lab.

Control/Reporter

Lentiviral Vector Amplification Protocol

AAV Infection Guideline

AAV Packaging Protocol

Selection-Drug Killing Curve

Lentivector Packaging Protocol

Lentivirus Infection Protocol

AAV-EF1a-Blank Control Vector

Quantity

Vector Map

Guarantee

List of Markers

AAV-EF1a-Blank-CBh-GFP Control Vector

Storage Condition

AAV-EF1a-Blank-SV40-Luc Control Vector

AAV-PGK-Blank Control Vector

AAV-PGK-Blank-CBh-GFP Control Vector

AAV-PGK-Blank-SV40-Luc Control Vector

AAV-hSyn-Blank-CBh-GFP Control Vector

AAV-hSyn-Blank-SV40-Luc Control Vector

<h2 dir="ltr">What Are AAV miRNA Negative Controls?</h2>
 MicroRNA (miRNA) research requires matched controls that enter the same delivery pathway as experimental constructs. AAV-delivered miRNA controls are particularly important for experiments in primary cells and in vivo models, where conventional transfection-based controls would not reflect the same delivery-related effects. The right miRNA control ensures accurate interpretation of miRNA-mediated effects. Choose a control matched to your expression and analysis workflow.
&nbsp;
<h2 dir="ltr">What you will find:</h2>
&nbsp;
<ul>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Serotype-Specific AAV miRNA Controls as blank control viruses used for precise tissue tropism matching.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
GFP-Tagged miRNA Control Viruses use fluorescent protein markers for successful transduction verification.
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
pAAV-mir-GFP-hGH-amp Plasmids used for reliable cloning and feature ampicillin resistance and hGH polyadenylation&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
miRNA-OFF Blank Control Vectors used to validate miRNA inhibition specificity&nbsp;
</li>
<li dir="ltr" style="font-family: arial, helvetica, sans-serif;" aria-level="1">
Ready-to-Use Control Virions used in comparative gene silencing for immediate use.
</li>
</ul>
<h2 dir="ltr"> How to Choose an AAV miRNA Negative Control</h2>
 Delivery Pathway Matching When miRNA is delivered via AAV, the control must also be AAV-delivered &mdash; to account for capsid-mediated innate immune activation and viral DNA sensing effects that alter cellular transcription independently of the miRNA sequence itself. Mimic vs. Inhibitor Format Non-targeting miRNA mimic controls (gain-of-function studies) and non-targeting miRNA inhibitor controls (loss-of-function studies) require different control designs matching the experimental approach. Serotype and Promoter Matching The AAV miRNA control should share the same serotype and promoter as the experimental AAV-delivered miRNA construct to ensure comparable tissue tropism and expression timing. In Vivo vs. In Vitro Application AAV-delivered miRNA controls are particularly relevant for in vivo gain-of-function or loss-of-function studies, where AAV's broad tissue tropism and long-term expression make it the delivery method of choice. Validation of Off-Target Effects As with other RNAi-pathway controls, non-targeting designs should be validated to have minimal homology to known miRNA targets in the relevant species. 
<h2 dir="ltr"> Specifications Context</h2>
&nbsp;
When miRNA is delivered via AAV, the control should also be AAV-delivered to account for vector-related effects such as capsid interactions and cellular responses to the viral genome. This distinguishes AAV-based controls from transfection-derived controls, which do not capture AAV-specific delivery effects. Matching the serotype and promoter configuration of the control vector to the experimental construct helps ensure that observed phenotypes are attributable to the miRNA rather than differences in vector design. Researchers planning in vivo studies should obtain control and experimental AAV preparations with comparable production and quality metrics where possible, as differences in titer or purity can introduce unwanted variability. Including both an AAV-delivered control and, where appropriate, an untreated cohort can further aid interpretation of miRNA-specific effects. Product availability reflects MBP's catalogue as of mid-2026. 
&nbsp;
<a href="https://mbpinc.net/contact-us">Contact the expert team</a> at MBP Inc. to discuss the most suitable AAV miRNA control constructs for your study and request a quote tailored to your research requirements.

ABM